Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials

Wilson, 1998, Prediction of coronary heart disease using risk factor categories, Circulation, 97, 1837, 10.1161/01.CIR.97.18.1837

Stamler, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022

1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025

1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA, 251, 365, 10.1001/jama.1984.03340270043026

Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8

2001, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486

2011, Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999-2002 and 2005-200, MMWR Morb Mortal Wkly Rep, 60, 109

Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001

Bell, 2012, Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia, Vasc Health Risk Manag, 8, 651

Akdim, 2010, Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia, Am J Cardiol, 105, 1413, 10.1016/j.amjcard.2010.01.003

Visser, 2010, Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia, J Lipid Res, 51, 1057, 10.1194/jlr.M002915

Raal, 2010, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial, Lancet, 375, 998, 10.1016/S0140-6736(10)60284-X

Akdim, 2010, Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy, J Am Coll Cardiol, 55, 1611, 10.1016/j.jacc.2009.11.069

Thomas, 2013, Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial, J Am Coll Cardiol, 62, 2178, 10.1016/j.jacc.2013.07.081

Visser, 2012, Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial, Eur Heart J, 33, 1142, 10.1093/eurheartj/ehs023

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097

Akdim, 2011, Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia, Eur Heart J, 32, 2650, 10.1093/eurheartj/ehr148

Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4

Stein, 2012, Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease, Circulation, 126, 2283, 10.1161/CIRCULATIONAHA.112.104125

McGowan, 2012, Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy, PLoS One, 7, e49006, 10.1371/journal.pone.0049006

Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002

FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm337195.htm. Accessed May 16, 2014.

Scientific conclusions and grounds for refusal presented by the European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/human/002429/WC500147552.pdf. Accessed May 16, 2014.

Hashemi, 2014, Liver histology during Mipomersen therapy for severe hypercholesterolemia, J Clin Lipidol, 8, 606, 10.1016/j.jacl.2014.08.002